O-(4-hydroxy-3-iodophenyl)-3-iodotyrosine | 70-40-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: O-(4-hydroxy-3-iodophenyl)-3-iodotyrosine
• 英文别名: (2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid
• CAS: 70-40-6
• 化学式: C₁₅H₁₃I₂NO₄
• 分子量: 525.08
• InChiKey: CPCJBZABTUOGNM-GFCCVEGCSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  92.8
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2922509090

文献信息

• [EN] TYPE III DEIODINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA DÉSIODINASE DE TYPE III ET LEURS UTILISATIONS
  申请人：HADASIT MED RES SERVICE

  公开号：WO2015140792A1

  公开（公告）日：2015-09-24

  The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.

  本发明涉及抑制第三型去碘酶（DIO3）活性的化合物。本发明还涉及治疗或预防抑郁症、与其他精神疾病或一般医学疾病相关的抑郁症、适合使用已知抗抑郁药物治疗的疾病或状况，以及癌症的方法，特别是通过使用本发明的化合物。
• Type III deiodinase inhibitors and uses thereof
  申请人：HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

  公开号：US10435365B2

  公开（公告）日：2019-10-08

  The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.

  本发明涉及抑制 III 型脱碘酶（DIO3）活性的化合物。本发明进一步涉及治疗或预防抑郁症、与其他精神或普通疾病或病症相关的抑郁症、可接受已知抗抑郁药治疗的病症和癌症的方法，特别是通过使用本发明的化合物。
• Diagnosis and treatment of human dormancy syndrome
  申请人：——

  公开号：US20030228628A1

  公开（公告）日：2003-12-11

  New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which subjects suffering from fibromyalgia, chronic fatigue, obesity, dementias including Alzheimer's Disease and related dormancy conditions are excluded, and the presence of one or more findings related to reduced activity including torpor, chronic fatigue, insulin resistance, dementias, obesity and the like. Treatment of human dormancy syndrome is directed toward increasing fT3 levels or decreasing rT3 levels, or both, using pharmaceutical and/or behavioral methods. Other conditions that are associated with HDS can also be treated using T3 therapy, with or without specific psychological, behavioral or pharmaceutical therapies.

  提供了诊断人类休眠综合征的新方法。人体休眠综合征的特征是，与正常人相比，血清中 rT3/fT3 的比率升高，而正常人中不包括纤维肌痛、慢性疲劳、肥胖、痴呆（包括阿尔茨海默病）和相关休眠病症的患者，并且存在一种或多种与活动减少有关的发现，包括倦怠、慢性疲劳、胰岛素抵抗、痴呆、肥胖等。人类休眠综合征的治疗方法是利用药物和/或行为方法提高 fT3 水平或降低 rT3 水平，或两者兼而有之。与人类休眠综合征相关的其他病症也可以使用 T3 疗法进行治疗，无论是否采用特定的心理、行为或药物疗法。
• 3,4-BROMO OR -SULFONATE SUBSTITUTED 1H-PYRROLE-2,5-DIONE DERIVATIVES AS TYPE III DEIODINASE (DIO3) INHIBITORS FOR TREATING DEPRESSIONS AND CANCER
  申请人：HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

  公开号：EP3119768B1

  公开（公告）日：2019-07-31
• TYPE III DEIODINASE INHIBITORS AND USES THEREOF
  申请人：Indian Institute of Science

  公开号：EP3119768A1

  公开（公告）日：2017-01-25